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Abstract
Background:  Case-control Genome-Wide Association Studies (GWAS) have identified single nucleotide
polymorphisms (SNPs) at the 9p21 locus as risk factors for coronary artery disease (CAD). The locus does not
contain a clear candidate gene. Hence, the results of GWAS have raised an intense interest in delineating the basis
for the observed association. We analyzed association of 4 SNPs at the 9p21 locus with the severity and
progression of coronary atherosclerosis, as determined by serial quantitative coronary angiograms (QCA) in the
well-characterized Lipoprotein Coronary Atherosclerosis Study (LCAS) population. The LCAS is a randomized
placebo-control longitudinal follow-up study in patients with CAD conducted to test the effects of fluvastatin on
progression or regression of coronary atherosclerosis.
Methods: Extensive plasma lipid levels were measured at the baseline and 2 1/2 years after randomization.
Likewise serial QCA was performed at the baseline and upon completion of the study. We genotyped the
population for 4 SNPs, previously identified as the susceptibility SNPs for CAD in GWAS, using fluorogenic 5'
nuclease assays. We reconstructed the haplotypes using Phase 2, analyzed SNP and haplotype effects using the
Thesias software as well as by the conventional statistical methods.
Results: Only Caucasians were included since they comprised 90% of the study population (332/371 with
available DNA sample). The 4 SNPs at the 9p21 locus were in tight linkage disequilibrium, leading to 3 common
haplotypes in the LCAS population. We found no significant association between quantitative indices of severity
of coronary atherosclerosis, such as minimal lumen diameter and number of coronary lesions or occlusions and
the 9p21 SNPs and haplotypes. Likewise, there was no association between quantitative indices of progression of
coronary atherosclerosis and the SNPs or haplotypes. Similarly, we found no significant SNP or haplotype effect
on severity and progression of coronary atherosclerosis.
Conclusion: We conclude the 4 SNPs at the 9p21 locus analyzed in this study do not impart major effects on
the severity or progression of coronary atherosclerosis. The effect size may be very modest or the observed
association of the CAD with SNPs at the 9p21 locus in the case-control GWAS reflect involvement of vascular
mechanisms not directly related to the severity or progression of coronary atherosclerosis.
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Background
Genome-wide association studies (GWAS), wherein the
alleles and genotypes frequencies of a large number of sin-
gle nucleotide polymorphisms (SNPs) in cases with the
phenotype, and in controls are compared, have emerged
as the state of the art approach to identify the susceptibil-
ity alleles for the common complex traits. Recently, sev-
eral large-scale GWAS have shown a very strong
association between coronary artery disease (CAD) and
SNPs at the 9p21 locus [1-4]. The observed association of
CAD or surrogate phenotypes with SNPs at the 9p21 locus
has been replicated and confirmed in a very large number
of populations, an important step toward validation of
the results of any association study [5-12]. The findings
have raised considerable interest in identifying the puta-
tive candidate susceptibility gene at the 9p21 locus, partic-
ularly considering that the region is sparse in genes. It is
comprised of only two known genes, namely, CDKN2A
[a.k.a. Alternative Reading Frame variant (ARF)] and
CDKN2B, which encode tumor suppressor proteins
p16INK2a and p16INK2b, respectively. The 9p21 locus is
frequently lost or mutated in various human cancers [13-
15]. Likewise, germ-line deletion of the locus in the
mouse leads to tumorigenesis but is not known to predis-
pose to or protect from atherosclerosis [16,17]. The locus
also contains a non-coding RNA gene with yet to be
defined function. Therefore, the weight of the very strong
genetic association is somewhat offset by the lack of a
clear biologically plausible candidate gene at the mapped
locus. Thus, there is a heightened interest in delineating
the basis for the reproducible results of case-control
GWAS and the putative mechanisms by which the 9p21
locus predisposes to CAD.
Detailed phenotyping is a crucial step not only in design
and interpretation of the results of any phenotype-geno-
type association study, but also in guiding the subsequent
studies to delineate the molecular mechanisms pertaining
to the observed association. Since the severity of athero-
sclerosis is a continuum, it would be expected that the
quantitative indices of severity of coronary atherosclerosis
to provide more robust analytic results than a dichoto-
mous definition used in the case-control GWAS studies.
Accordingly, a previous study analyzed association of the
SNPs at the 9p21 locus with coronary calcium score on
computerized tomography as a quantitative surrogate
index for coronary atherosclerosis [5]. Coronary calcium
score, however, was analyzed as a categorical phenotype
and allele frequencies were compared in those with 0, 1–
100 and > 100 coronary calcium scores [5]. In the present
study, we used quantitative coronary angiography (QCA),
one of the most robust and commonly used method for
accurate quantification of severity of coronary atheroscle-
rosis, to assess the severity of coronary atherosclerosis
[18]. Therefore, we hypothesized that the SNPs at the
9p21 locus, implicated as susceptibility SNPs in the case-
control GWAS [1-4], are associated with the baseline
severity as well as progression of coronary atherosclerosis,
as determined by QCA. To test this hypothesize, we deter-
mined association of quantitative indices of severity of
coronary atherosclerosis as well as progression of coro-
nary atherosclerosis over a 2 1/2 year period with 4 SNPs




332 Caucasian individuals who participate in the Lipo-
protein and Coronary Atherosclerosis Study (LCAS) com-
prised the study population. The study design and the
main results of the LCAS have been published [19]. In
brief, 429 males and females between the ages of 35 to 75
years who had at least 1 coronary lesion causing 30% to
75% luminal diameter stenosis on QCA and had a plasma
low-density lipoprotein-cholesterol (LDL-C) level of 115
to 190 mg/dl despite diet participated in LCAS. DNA sam-
ples were available in 371 subjects. To avoid the potential
confounding effects of ethnic background and given that
the GWAS of CAD were performed mostly in Caucasians,
we included only Caucasians, who comprised 90% of the
study population (N = 332). We measured total choles-
terol, LDL-C, high-density lipoprotein-cholesterol (HDL-
C), triglyceride (TG), lipoprotein (a) (Lp [a]), and apoli-
poprotein levels in all participants and quantitative indi-
ces of severity of coronary atherosclerosis in 288
participants at the baseline. We then randomized the par-
ticipants to treatment with either fluvastatin (40 mg daily)
or placebo and repeated the detailed phenotyping after
2.5 years of therapy. The study protocol was approved by
the institutional review board, and all participates were
provided with written informed consent that included
genetic studies.
Genotyping
In the case-control GWAS, 4 SNPs, namely rs2383206
(chromosomal position: 22,105,026), rs2383207 (chro-
mosomal position: 22,105,959), rs10757278 (chromo-
somal position: 22,114,477), rs1333049 (chromosomal
position: 22,115,503) were the primary risk SNPs at the
9p21 locus [1-4]. All chromosomal positions were per ref-
erence assembly (build 36.3). We genotyped the putative
risk SNPs by fluorogenic 5' nucleotidase (Taqman) assays
using an ABI PRISM® 7900 HT Real-Time PCR instrument.
The PCR conditions were 1 cycle at 95°C for 10 min, fol-
lowed by 40 cycles of 92°C for 15 sec and 60°C for 1 min
as recommended by the manufacturer (Applied Biosys-
tems, Foster City, CA). An investigator who had no knowl-
edge of the angiographic and clinical data performed the
genotyping.BMC Cardiovascular Disorders 2009, 9:3 http://www.biomedcentral.com/1471-2261/9/3
Page 3 of 10
(page number not for citation purposes)
Linkage disequilibrium (LD), haplotype reconstruction and 
statistical genetics
We estimated LD between the SNPs by the expectation
maximization (EM) algorithm using Arlequin 2.0 [20].
Deviation from Hardy-Weinberg equilibrium was esti-
mated by χ2 test. We used PHASE 2.1 to reconstruct and
determine frequencies of the haplotypes. It implements
Bayesian statistical method to infer phase and reconstruct
haplotypes from population genetics by the Markov
Chain-Monte Carlo algorithm and coalescent theory, with
partition ligation algorithm. We detected the haplotype
effect size using the Thesias program, which is based on
the maximum likelihood model and is linked to the sto-
chastic version of the expectation maximization algo-
rithm [21,22].
Conventional statistical analysis
We expressed the continuous variables as mean ± SD and
determined variance equality by the Bartlett's test. We
compared the differences among the non-parametric var-
iables with equal variances among the three genotypes by
the analysis of variance followed by pair wise compari-
sons (Bonferroni method). We compared the differences
among the phenotypes with unequal variances by the
Kruskal-Wallis test. We analyzed the differences in the
parametric variables among the three genotypes by Chi
Square test. We also performed multivariate robust and
logistic regression analysis to detect independent associa-
tion of the SNPs and demographic variables with indices
of severity of coronary artery disease and its progression.
We used a general genetic model by assigning indicators
0, 1 and 2 to the genotypes and avoided assuming a dom-
inant or a recessive effect in the absence of biological evi-
dence. Statistical analysis was performed using STATA
program v9.2.
Results
Baseline characteristics of the study population
Demographics, plasma lipid levels and indices of severity
of coronary atherosclerosis at the baseline are shown in
Table 1.
Linkage disequilibrium and haplotypes
We selected the rs2383206, rs2383207, rs10757278 and
rs1333049 because they were associated with the risk of
ischemic heart disease/CAD in the case-control GWAS [1-
4]. The GG genotype and the G allele frequencies were
higher in the cases than in the controls in GWAS, the latter
by approximately 5% [1-4]. The frequency of the G allele
(rs238206) in the LCAS population was 0.551, which is
largely in accord with the observed frequency in the US
population [3]. The position of the SNPs on the references
assembly and LD between the SNPs in the LCAS popula-
tion are shown in Figure 1. The 4 SNPs spanned 10,477 bp
of DNA at the 9p21 locus and encompassed 11 additional
SNPs listed in the HapMap database. All SNPs were in
strong LD with each other and also captured all of the 11
other alleles in this region with a mean maximum r2 of
0.932. As would be expected, there were no significant dif-
ferences in genotype-phenotype association among the 4
SNPs. Therefore, data for the phenotype-genotype associ-
ation is shown only for rs238206 SNP (phenotypic data
for 3 other SNPs are available upon request). Haplotype
reconstruction using Phase 2.1 showed 3 common haplo-
types of G-G-G-A, f = 0.506; A-A-A-G, f = 0.442 and G-G-
A-G, f = 0.038) and 5 rare haplotypes (detail data availa-
ble upon request).
Genotype-phenotype association
Demographic characteristics, plasma levels of lipid and
angiographic indices of severity of coronary atherosclero-
sis at the baseline were not significantly different among
the genotypes of any of the 4 SNPs analyzed. The results
for the rs238206 SNP are shown in Table 2. Likewise, as
would be expected because of strong LD among the 4
SNPs, we detected no significant haplotype effect on
quantitative indices of severity of coronary atherosclerosis
(data available upon request).
Genotypes and progression of coronary atherosclerosis
There were no significant differences in the mean number
of new coronary lesions or coronary occlusions and the
number of individuals who developed new lesions or new
occlusions during the 2.5-year follow up period among
the genotypes (Table 3). Similarly, there was no signifi-
cant haplotype effect on progression of coronary athero-
sclerosis (data available upon request).
Genotype and response to fluvastatin therapy
Treatment with fluvastatin reduced plasma LDL-C levels
by 25.7% (p < 0.0001), raised HDL-C by 9.3% (p <
0.0003) and slowed progression of atherosclerosis (MLD
loss -0.04 mm vs. -0.11 mm in the placebo, p = 0.009).
However, there were no genotype-by-treatment interac-
tions in changes in plasma levels of lipid among the gen-
otypes, with the exception of plasma levels of
triglycerides, which showed a significant genotype-
dependent change (for all 4 SNPs). Likewise, changes in
quantitative indices of severity of coronary atherosclerosis
were not significantly different among the genotypes of
the 4 SNPs. Data for changes in the plasma lipid levels and
indices of severity of atherosclerosis according to the gen-
otypes of rs238206 SNP are shown in Table 4. Finally,
only treatment with fluvastatin (regression coefficient:
0.082, 95% CI: [0.028–0.136], t = 3.02, p = 0.003) and
plasma HDL-C levels at the baseline (regression coeffi-
cient: 0.004, 95% CI: [0.002 – .006], t = 3.51, p = 0.001)
were the only independent predictors of progression of
coronary atherosclerosis (ΔMLD during the follow up) in
robust regression analysis but not any of the 4 SNPs or theBMC Cardiovascular Disorders 2009, 9:3 http://www.biomedcentral.com/1471-2261/9/3
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Table 1: Demographics, Baseline Plasma Lipid Levels and Indices of Severity of Coronary Atherosclerosis
A. Demographics (N = 332)
Age (years) 59.3 ± 7.7
Male/Female 280 (84%)/52 (16%)
Height (m) 1.74 ± 0.08
Body Weight (kg) 84.85 ± 15.62
Body mass index (kg/m2) 28.06 ± 4.50
Waist/Hip 0.91 ± 0.68
Systolic blood pressure (mmHg) 124.48 ± 15.31
Diastolic blood pressure (mmHg) 76.67 ± 8.82
Previous myocardial infarction (%) 130 (39%)
Diabetes mellitus (%) 11 (3.3%)
Current smokers (%) 68 (20%)
B. Plasma Lipid levels (N = 332)
Total Cholesterol (mg/dl) 220.0 ± 24.5
HDL-C (mg/dl) 43.9 ± 11.3
LDL-C (mg/dl) 143.9 ± 19.9
LDL-C/HDL-C 3.49 ± 0.91
Triglyceride (mg/dl) 161.5 ± 57.1
Apo A1 (mg/dl) 132.7 ± 27.4
Apo B (mg/dl) 134.4 ± 20.8
ApoB/ApoA1 1.05 ± 0.26
Apo C-III (mg/dl) 37.5 ± 12.3
Lipoprotein (a) (mg/dl) 132.7 ± 27.4
C. Quantitative Indices of Severity of Atherosclerosis (N = 288)
Number of coronary lesions (mean) 2.99 ± 1.37
Number of subject with ≥ one coronary lesion (%) 287 (86%)
Number of coronary occlusions (mean) 0.30 ± 0.55
Number of subject with ≥ one coronary occlusion (%) 83 (25%)
Average baseline MLD (mm) 1.68 ± 0.40
Abbreviations: m: meter; Kg: Kilogram; mmHg: millimeter mercury; mg/dl: milligram per deciliter; HDL-C: High-density lipoprotein-cholesterol; 
LDL-C: low-density lipoprotein-cholesterol; Apo A: apolipoprotein A; Apo B: apolipoprotein B; Apo C-III: apolipoprotein C3; MLD: minimal lumen 
diameter.BMC Cardiovascular Disorders 2009, 9:3 http://www.biomedcentral.com/1471-2261/9/3
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demographic variables sex, age, body mass index, diabe-
tes, smoking, alcohol consumption and the baseline
plasma levels of LDL-C and triglyceride.
Discussion
We determined the association of quantitative indices of
severity of coronary atherosclerosis, as determined by
serial QCA, with 4 SNPs at the 9p21 locus; previously
shown to be associated with the risk of CAD in case-con-
trol GWAS [1-4,11,12]. We found no significant associa-
tion between the quantitative indices of severity of
coronary atherosclerosis and the SNPs at the 9p21 in the
well-characterized LCAS population. The availability of
serial QCA also provided the opportunity to examine the
potential association of development of new coronary
lesions and progression of the existing coronary lesions.
We found no significant SNP and haplotype effect on the
development of new coronary lesions and the progression
of coronary atherosclerosis over a period of 2 1/2 years
neither in the placebo group nor in the entire population
when treatment with fluvastatin was included as a covari-
ate. In contrast, plasma HDL-C levels and treatment with
fluvastatin were the only independent predictors of pro-
gression of coronary atherosclerosis (inverse relation-
ship). There were also no genotype-by-treatment
interactions between the 4 SNPs at the 9p21 locus and the
response of coronary atherosclerosis to treatment with
fluvastatin. Moreover, we detected no significant associa-
tion between the 9p21 locus SNPs and plasma levels of
total cholesterol, HDL-C, LDL-C, triglycerides or apolipo-
proteins. The findings suggest absence of a strong associa-
tion between the severity, development or progression of
coronary atherosclerosis, as determined by QCA, and the
4 SNPs at the 9p21 locus.
The results of the present study is in accord with the
results of a recent study showing no significant associa-
tion between the severity of carotid atherosclerosis as
determined by the measurement of carotid intima-media
thickness by ultrasound and the 4 SNPs at the 9p21 locus
[23]. The null results of these two studies should be
weighed against the results of the case-control GWAS
showing a strong association between the 9p21 locus and
risk of CAD. The previous null study had a very large sam-
ple size [23] and low chance of type II statistical error. It is
also noteworthy that the Ottawa Heart Study-1 and
Ottawa Heart Study-2 each had a sample size of approxi-
mately 320 cases and controls [2]. Despite the modest
Chromosomal positions of the 4 SNPs analyzed and linkage disequilibrium (LD) Figure 1
Chromosomal positions of the 4 SNPs analyzed and linkage disequilibrium (LD). The chromosomal positions of 
rs2383206, rs2383207, rs10757278, rs1333049 according to reference assembly are shown along with the D' values indicating 
near perfect LD among the 4 SNPs. The positions of the 3 adjacent genes are also shown, none of which is a biologically plau-
sible candidate gene for coronary atherosclerosis or its thrombotic complications.
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Table 2: Clinical Phenotypes and Genotypes of rs2383206 SNP at the 9p21 Locus
Genotypes
GG GA AA P
N-332 88 190 54
A. Demographics
Age 58.57 ± 7.89 59.42 ± 7.48 60.11 ± 7.75 0.482
Male/Female 72/16 161/29 47/7 0.689
Height (m) 1.73 ± 0.09 1.74 ± 0.08 1.73 ± 0.08 0.462
Body weight (kg) 84.12 ± 15.88 85.43 ± 16.11 84.00 ± 13.68 0.737
BMI (Kg/m2) 27.97 ± 4.34 28.08 ± 4.59 28.12 ± 4.50 0.976
Hip/Waist 1.11 ± 0.09 1.10 ± 0.09 1.11 ± 0.09 0.649
Systolic BP (mmHg) 125.34 ± 15.18 124.03 ± 15.65 124.70 ± 14.55 0.797
Diastolic BP (mmHg) 77.64 ± 8.59 76.34 ± 8.64 76.30 ± 9.37 0.492
Previous MI (%) 35(39.75) 73(38.4) 22(40.7) 0.945
Diabetes Mellitus (%) 5 (1.5) 5 (1.5) 1 (0.3) 0.337
Current smoker (%) 19 (21.6) 40 (21.1) 9 (16.7) 0.746
B. Plasma Lipid levels
Total Cholesterol (mg/dl) 222.05 ± 23.74 220.14 ± 23.98 216.19 ± 23.74 0.384
HDL-C (mg/dl) 44.27 ± 12.85 43.69 ± 11.24 43.80 ± 8.72 0.716*
LDL-C (mg/dl) 144.78 ± 19.74 144.02 ± 20.08 144.78 ± 19.74 0.750
LDL-C/HDL-C 3.53 ± 0.97 3.50 ± 0.92 3.39 ± 0.79 0.647
Triglyceride (mg/dl) 165.20 ± 64.87 162.33 ± 55.60 151.23 ± 48.01 0.691*
Apo A1 (mg/dl) 136.03 ± 31.37 131.81 ± 27.20 130.56 ± 20.40 0.619*
Apo B (mg/dl) 137.19 ± 22.16 134.17 ± 20.36 130.31 ± 19.44 0.157
ApoB/ApoA1 1.05 ± 0.26 1.06 ± 0.26 1.02 ± 0.23 0.666
Apo C-III (mg/dl) 37.95 ± 13.36 38.28 ± 12.25 33.67 ± 9.85 0.0465
Lipoprotein (a) (mg/dl) 40.07 ± 37.38 33.34 ± 31.98 33.87 ± 27.08 0.253*
C. Quantitative Indices of Severity of Atherosclerosis
N = 288 77 162 49
Number of coronary lesions (mean) 3.09 ± 1.43 2.93 ± 1.37 3.06 ± 1.30 0.639BMC Cardiovascular Disorders 2009, 9:3 http://www.biomedcentral.com/1471-2261/9/3
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sample sizes there were significant differences in the dis-
tribution of genotypes of the 9p21 locus SNPs between
the cases and controls in both datasets [2]. Nonetheless,
we considered the possibility of type II statistical error in
the present study. Therefore, we calculated the power of
the present study, post hoc, to detect differences in MLD,
the primary quantitative phenotype of severity of coro-
nary atherosclerosis. Accordingly, the number of observed
genotypes in the study population provided 95.5%,
92.9% and 73.9% power to detect a 20% difference in the
baseline MLD between subjects with the GG vs. GA, GA
vs. AA and GG vs. AA genotypes, respectively, and 98.1%
between GG vs. GA and AA genotypes, when α is set at
0.05. Likewise, the power to detect a 15% difference in
mean MLD between GG vs. GA and AA genotypes was
86%. For a 10% or smaller differences in the mean MLD
among the genotypes, the sample size of the present study
did not offer sufficient power. Therefore, we can not
exclude the possibility that the 9p21 locus imparts an
effect on MLD that is less than 10% (0.165 mm). Hence,
smaller differences among the genotypes are beyond the
level of detection of the present study. The presence of
undetected small differences in the MLD among the gen-
otype may impart clinical significance and affect the clin-
ical outcome. As for the progression of coronary
atherosclerosis during the follow up period, the time
interval between the two QCA was 2.5 years, which was
sufficient to detect the effects of treatment and plasma
HDL-C levels. Accordingly, one would have expected to
detect the effects of SNPs at 9p21 locus on progression of
coronary atherosclerosis if they were greater than the
effects of treatment or plasma HDL-C levels. Smaller
effects, however, could remain undetected. We also note
that while QCA is a robust tool for the measurement of
lumen diameter and area, but it may not be sufficiently
sensitive to changes in plaque burden. As for the plasma
LDL-C and HDL-C levels, the sample size of the study pro-
vided 80% power to detect approximately 8 mg/dl and 4
mg/dl differences between the two common genotypes of
the SNPs, respectively. Overall, we noted no trend toward
≥ 1 coronary lesion (%) 77 (87.5) 161 (84.7) 49 (90.7) 0.495
Number of coronary occlusions(mean) 0.34 ± 0.59 0.27 ± 0.54 0.30 ± 0.50 0.636
≥ 1 coronary occlusion (%) 25 (28.4) 43 (22.6) 15 (27.8) 0.513
Baseline MLD (mm) 1.65 ± 0.39 1.69 ± 0.40 1.68 ± 0.40 0.819
Abbreviations: BMI: Body mass índex; BP: Blood pressure; MI: Myocardial infarction; other abbreviations are as in Table 1
* indicates p value by non-parametric Kruskal-Wallis test
Table 2: Clinical Phenotypes and Genotypes of rs2383206 SNP at the 9p21 Locus (Continued)
Table 3: Progression (Regression) of Atherosclerosis Over a 2.5-Year Period (in the Placebo Group) According to the Genotypes of 
rs2383206 SNP at the 9p21 Locus
Genotypes
GG GA AA P
N = 141 32 78 31
New coronary lesion (mean) 0.34 ± 0.48 0.38 ± 0.49 0.26 ± 0.45 0.462
Subjects with new coronary lesions (%) 11 (34.3) 30 (38.4) 8 (25.8) 0.265
New coronary occlusions (mean) 0.03 ± 0.18 0.08 ± 0.27 0.06 ± 0.25 0.678
Subjects with new coronary occlusions (%) 1 (3.1) 6 (7.7) 2 (6.5) 0.209
Average final MLD (mm) 1.54 ± 0.40 1.62 ± 0.41 1.59 ± 0.39 0.657
Change in MLD (mm) -0.09 ± 0.25 -0.11 ± 0.23 -0.11 ± 0.25 0.928
Abbreviations: m: meter; Kg: Kilogram; mmHg: millimeter mercury; mg/dl: milligram per deciliter; HDL-C: High-density lipoprotein-cholesterol; 
LDL-C: low-density lipoprotein-cholesterol; Apo A: apolipoprotein A; Apo B: apolipoprotein B; Apo C-III: apolipoprotein C3; MLD: minimal lumen 
diameter.BMC Cardiovascular Disorders 2009, 9:3 http://www.biomedcentral.com/1471-2261/9/3
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an association for any of the quantitative indices of sever-
ity of coronary atherosclerosis or plasma levels of lipid to
suggest the possibility of type II statistical error. Finally,
we note the prospective design of the present study
wherein each individual was his/her own control as
regards the progression of coronary atherosclerosis and
the detailed phenotypic definition of atherosclerosis as a
continuous phenotype as potential strengths of the
present study.
Various phenotypes including ischemic stroke, abdomi-
nal aortic aneurysm, intra-cranial aneurysm, coronary
artery calcification, osteoporosis, type 2 diabetes mellitus
and possibly Alzheimer's disease have been associated
with the 9p21 locus [5,24-28]. Many but not all of the
associated phenotypes may share a common vascular eti-
ology with atherosclerosis as an underpinning milieu. The
9p21 locus contains the tumor suppressor proteins
p16INK4a and P16INK4b, which are frequently lost or
mutated in various human cancers, such as in leukemia,
glioma, head and neck cancers and bladder cancers [13-
15]. The naturally occurring mutations at this locus are
not known to predispose to premature atherosclerosis.
Similarly, genetic deletion of the locus in the mouse is not
known to predispose to or protect from atherosclerosis
[16,17]. Accordingly, given that LD in the human genome
can span large chromosomal segments [29], one may
speculate that the 9p21 locus is in LD with a remote locus
that serves as a true susceptibility locus for coronary
atherosclerosis. Alternatively, the locus also contains a
Table 4: Response of Plasma Lipid and Coronary Atherosclerosis to Treatment with Fluvastatin According to Genotypes of rs2383206 
SNP at the 9p21 Locus
Genotypes
GG GA AA P
A. Response of plasma lipids levels
N = 165 51 97 17
% Change in total cholesterol -14.7 ± 10.7 -16.5 ± 14.9 -15.4 ± 10.6 0.183*
% Change in LDL-C -25.8 ± 13.8 -26.1 ± 20.2 -23.2 ± 14.5 0.040*
% Change in HDL-C 9.2 ± 14.6 9.9 ± 16.1 6.7 ± 15.0 0.734
% Change in Triglyceride 9.6 ± 42.9 5.4 ± 36.0 5.1 ± 24.8 0.002*
% Change in apoB -16.4 ± 14.0 -16.9 ± 17.1 -13.6 ± 11.6 0.737
% Change in apo A1 8.1 ± 16.5 6.4 ± 22.0 4.5 ± 16.0 0.801
B. Response of coronary atherosclerosis
N = 147 46 84 17
New coronary lesions (mean) 0.30 ± 0.47 0.25 ± 0.45 0.24 ± 0.44 0.768
Subjects with new coronary lesions (%) 14 (30.4) 21 (25.0) 4 (23.5) 0.664
New coronary occlusions (mean) 0.04 ± 0.21 0.04 ± 0.19 0.0 ± 0.0 0.698
Subjects with new coronary occlusions (%) 2 (4.4) 3 (3.7) 0 (0) 0.694
Average final MLD (mm) 1.54 ± 0.44 1.60 ± 0.47 1.76 ± 0.50 0.396
Change in MLD (mm) -0.04 ± 0.27 -0.05 ± 0.26 -0.01 ± 0.20 0.807
Abbreviations: m: meter; Kg: Kilogram; mmHg: millimeter mercury; mg/dl: milligram per deciliter; HDL-C: High-density lipoprotein-cholesterol; 
LDL-C: low-density lipoprotein-cholesterol; Apo A: apolipoprotein A; Apo B: apolipoprotein B; Apo C-III: apolipoprotein C3; MLD: minimal lumen 
diameter.BMC Cardiovascular Disorders 2009, 9:3 http://www.biomedcentral.com/1471-2261/9/3
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gene that transcribes a non-coding RNA, with yet to-be-
defined function. Whether one of the two known genes or
the non-coding RNA at the 9p21 locus or a distant locus/
gene in LD with the 9p21 locus is responsible for the
observed and consistent association of the 9p21 locus
with CAD remains to be established.
The most significant impact of the results of the GWAS is
likely to be in elucidation of the novel mechanistic path-
ways involved in the pathogenesis of atherosclerosis and
its thrombotic complications. Such mechanistic studies
could lead to identification of new therapeutic targets and
the development of new drugs. In general, the clinical util-
ity of the results of GWAS for risk stratification and prog-
nostication is expected to be relatively modest; partly
because of the low pre-test likelihood of the clinical events
and relatively modest impact of the vast majority of the
risk alleles for a complex trait. Therefore, delineation of
molecular mechanisms by which the 9p21 locus imparts
susceptibility to broadly defined CAD could have consid-
erable clinical implications. An integral part of and likely
a pre-requisite for the mechanistic studies pursuant to the
results of the GWAS is identification of the precise pheno-
type of coronary heart disease that is associated with the
9p21 locus.
Conclusion
The results of the present study show no significant asso-
ciation between the quantitative indices of severity of cor-
onary atherosclerosis and the 4 SNPs at the 9p21 locus,
previously identified as susceptibility SNPs for coronary
heart disease in case-control GWAS. The null results of the
present study along with the null results of a recent study
showing no association between carotid intima-media
thickness and the 9p21 locus [23] suggest that the
observed association of 9p21 locus with CAD in the
GWAS could be mediated through complex mechanisms
beyond the severity or progression of atherosclerosis. We
suggest mechanistic studies are needed to delineate the
potential role of the SNPs at the 9p21 locus on plaque
instability and intra-arterial thrombosis.
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